SG10202004611SA - Multiple oligonucleotide moieties on peptide carrier - Google Patents

Multiple oligonucleotide moieties on peptide carrier

Info

Publication number
SG10202004611SA
SG10202004611SA SG10202004611SA SG10202004611SA SG10202004611SA SG 10202004611S A SG10202004611S A SG 10202004611SA SG 10202004611S A SG10202004611S A SG 10202004611SA SG 10202004611S A SG10202004611S A SG 10202004611SA SG 10202004611S A SG10202004611S A SG 10202004611SA
Authority
SG
Singapore
Prior art keywords
peptide carrier
multiple oligonucleotide
oligonucleotide moieties
moieties
peptide
Prior art date
Application number
SG10202004611SA
Inventor
Timothy E Weeden
Carol A Nelson
Bruce M Wentworth
Nicholas P Clayton
Andrew Leger
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG10202004611SA publication Critical patent/SG10202004611SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
SG10202004611SA 2014-05-23 2015-05-22 Multiple oligonucleotide moieties on peptide carrier SG10202004611SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462002296P 2014-05-23 2014-05-23

Publications (1)

Publication Number Publication Date
SG10202004611SA true SG10202004611SA (en) 2020-06-29

Family

ID=53366294

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608880VA SG11201608880VA (en) 2014-05-23 2015-05-22 Multiple oligonucleotide moieties on peptide carrier
SG10202004611SA SG10202004611SA (en) 2014-05-23 2015-05-22 Multiple oligonucleotide moieties on peptide carrier

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608880VA SG11201608880VA (en) 2014-05-23 2015-05-22 Multiple oligonucleotide moieties on peptide carrier

Country Status (15)

Country Link
US (2) US20170182171A1 (en)
EP (1) EP3151841B1 (en)
JP (2) JP6825914B2 (en)
KR (1) KR102487942B1 (en)
CN (1) CN106459975B (en)
AR (1) AR101542A1 (en)
AU (1) AU2015263963B2 (en)
BR (1) BR112016027236A2 (en)
CA (1) CA2949104C (en)
IL (1) IL249064B (en)
MX (1) MX2016015156A (en)
RU (2) RU2020142530A (en)
SG (2) SG11201608880VA (en)
TW (1) TWI726844B (en)
WO (1) WO2015179742A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179742A1 (en) 2014-05-23 2015-11-26 Genzyme Corporation Multiple oligonucleotide moieties on peptide carrier
AU2018337854A1 (en) * 2017-09-22 2020-03-19 Katarzyna JASTRZEBSKA Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
CN112105625A (en) * 2018-03-07 2020-12-18 赛诺菲 Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same
US10765760B2 (en) * 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
CN114728999A (en) * 2019-09-05 2022-07-08 赛诺菲 Oligonucleotides containing nucleotide analogs
WO2021211572A1 (en) * 2020-04-14 2021-10-21 Oregon State University Antisense therapeutics for the treatment of coronavirus
WO2023034515A2 (en) * 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006056A1 (en) * 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
DE19935302A1 (en) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Conjugates and processes for their preparation and their use for the transport of molecules across biological membranes
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
ES2694726T3 (en) 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
WO2009147368A1 (en) 2008-06-04 2009-12-10 Medical Research Council Peptides
JP5864257B2 (en) 2008-10-24 2016-02-17 サレプタ セラピューティクス， インコーポレイテッド Multiple exon skipping compositions for DMD
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
CA2848753C (en) * 2011-09-14 2022-07-26 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
KR102240217B1 (en) * 2012-09-25 2021-04-14 젠자임 코포레이션 Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
CA2935426C (en) * 2014-01-30 2023-07-25 F. Hoffmann-La Roche Ag Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
WO2015179742A1 (en) 2014-05-23 2015-11-26 Genzyme Corporation Multiple oligonucleotide moieties on peptide carrier

Also Published As

Publication number Publication date
CA2949104C (en) 2023-09-26
MX2016015156A (en) 2017-03-27
RU2020142530A (en) 2021-04-26
RU2016150629A3 (en) 2018-12-24
AU2015263963A1 (en) 2016-12-01
AU2015263963B2 (en) 2021-02-18
SG11201608880VA (en) 2016-11-29
AR101542A1 (en) 2016-12-28
JP7269968B2 (en) 2023-05-09
KR20170005118A (en) 2017-01-11
CA2949104A1 (en) 2015-11-26
KR102487942B1 (en) 2023-01-11
US20170182171A1 (en) 2017-06-29
US20190388547A1 (en) 2019-12-26
JP6825914B2 (en) 2021-02-03
CN106459975B (en) 2020-03-27
IL249064B (en) 2021-07-29
JP2021063128A (en) 2021-04-22
IL249064A0 (en) 2017-01-31
TW201617373A (en) 2016-05-16
CN106459975A (en) 2017-02-22
EP3151841B1 (en) 2022-10-19
TWI726844B (en) 2021-05-11
EP3151841A1 (en) 2017-04-12
BR112016027236A2 (en) 2017-10-17
WO2015179742A1 (en) 2015-11-26
JP2017517253A (en) 2017-06-29
RU2016150629A (en) 2018-06-25
RU2739987C2 (en) 2020-12-30
US11103587B2 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
HK1252759A1 (en) Peptide oligonucleotide conjugates
GB201503408D0 (en) Oligonucleotides
GB201420312D0 (en) Carrier Mounting
IL249064A0 (en) Multiple oligonucleotide moieties on peptide carrier
PT3215316T (en) Printed abrasive article
GB201614100D0 (en) Carriers
IL284753A (en) Peptide oligonucleotide conjugates
GB201502252D0 (en) Carrier
GB201504124D0 (en) Oligonucleotides
SG11201609592YA (en) Spud carrier system
PL3127092T3 (en) Data carrier
EP4039224C0 (en) Workpiece carrier
GB201410317D0 (en) Substrate
SG11201801454QA (en) Substrate carrier
GB2532841B (en) Carrier system
HUE038296T2 (en) Wheel carrier
HK1212312A1 (en) Refillable material transfer system
SG11201700652PA (en) Modified antimir-138 oligonucleotides
GB2531577B (en) Transfer case
GB201419736D0 (en) Secure id labeling
GB201509256D0 (en) Multiple carrier
SG11201610824VA (en) Data carrier
GB201412744D0 (en) Bicycle carrier
PL3108546T3 (en) System comprising a contact carrier and a corresponding contact carrier
PL3183694T3 (en) Data carrier comprising a partial piece